First human test of new oral weight loss pill begins

NCT ID NCT05184322

Summary

This early-stage study tested the safety of a new oral medication called ecnoglutide in 87 healthy adults. The medication is being developed to help manage type 2 diabetes and obesity. Researchers gave participants increasing doses to check for side effects and see how the body processes the drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane)

    Herston, Queensland, 4006, Australia

Conditions

Explore the condition pages connected to this study.